Recent analyses of our microRNA (miRNA) expression signatures obtained from several types of cancer have provided novel information on their molecular pathology.
recurrent RCC. However, the therapeutic benefits are limited, and RCC is generally insensitive to radiation and chemotherapy. Thus, development of novel therapeutic strategies is needed. 2 We believe that novel genomic approaches are required to elucidate the underlying molecular mechanism of metastatic RCC.
MicroRNA (miRNA) is a single-stranded low molecular RNA of [19] [20] [21] [22] bases that possesses important functions. For example, miRNA regulates the expression of target genes by inhibiting translation and/or accelerates the degradation of functional RNAs (protein coding/non-protein coding genes). 4, 5 In human cells, a single miRNA can regulate many different protein-coding or non-coding mRNAs and a single mRNA can be regulated by several different miRNAs. 6 Thus, aberrant expression of miRNA could disrupt regulated RNA networks in cancer cells. Therefore, it is important to elucidate the aberrant expression of miRNAs in each type of cancer to better understand the molecular mechanism of cancer pathogenesis. 4, 7, 8 We previously identified antitumor miRNAs that regulated novel oncogenic pathways based on miRNA expression signatures. [9] [10] [11] [12] Downregulation of miR-451a was detected by our studies of miRNA signatures and several types of cancers. [12] [13] [14] [15] [16] [17] [18] Moreover, a large cohort analysis using The Cancer Genome Atlas (TCGA) database (https://cancergenome.nih.gov/) showed that low expression of miR451a was associated with poor survival of patients with RCC. The antitumor role of miR-451a in RCC has been reported; 19 however, T2a  a  0  1  eg  1  0  0  0  0   10  77  M  G1 > G2  T1b  a  0  0  eg  1  0  0  0  0   11  77  M  G2 > G1  T3a  a  1  0  eg  1  0  0  0  0   12  51  M  G2 > G1  T1  a  0  0  eg  0  0  0  0  0   13  78  M  G2 > G1 > G3  T1b  b  0  0  eg  1  0  0  0  0   14  57  M  G1 > G2  T1a  a  0  0  eg  1  0  0  0  0   15  54  M  G2 > G1  T3a  a  0  0  eg  0  0  1  0  0 eg, expansive growth; F, female; fc, capsular formation; ig, infiltrative growth; im, intrarenal metastasis; INF, infiltration; ly, lymph node; M, male; rc, renal capsule invasion; rp, pelvis invasion; s, sinus invasion; v, vein.
Lipofectamine 3000 reagent (Invitrogen) by forward transfection following the manufacturer's protocol.
| Quantitative real-time RT-PCR
Total RNA was extracted from human tissues and cell lines using TRIzol reagent (Invitrogen) according to the manufacturer's protocol, as we described previously. [20] [21] [22] [23] [24] [25] The procedure for PCR quantification has been outlined. Expression levels of miR-451a (assay ID:001141; Applied Biosystems) were analyzed by TaqMan quantitative real-time RT-PCR (qRT-PCR) (TaqMan MicroRNA Assay; Applied Biosystems) and normalized to the expression of RNU48 (assay ID:
001006; Applied Biosystems). TaqMan probes and primers for PMM2 (P/N: Hs00756707_m1; Applied Biosystems), GAPDH (internal control; P/N: Hs02758991_m1; Applied Biosystems), and GUSB (internal control; P/N: Hs00939627_ml; Applied Biosystems) were assay-on-demand gene expression products. The relative expression levels were calculated using the 2 ÀDDCT method.
| Cell proliferation, migration, and invasion assays
Cell proliferation, migration, and invasion assays have been described.
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F I G U R E 1 Antitumor functions of miR-451a in renal cell carcinoma. A, Expression levels of miR-451a in renal cell carcinoma clinical specimens and cell lines. RNU48 was used as an internal control. B, Kaplan-Meier survival curves, as determined using data from The Cancer Genome Atlas database. C, Cell proliferation was determined by XTT assays 72 hours after transfection with miR-451a. D, Cell migration activity. E, Cell invasion activity was determined using Matrigel assays. *P < .0001
2.5 | Identification of putative target genes regulated by miR-451a in RCC cells
To identify miR-451a target genes, we used in silico analyses and genome-wide gene expression analyses, as outlined previously. [20] [21] [22] [23] [24] [25] We used the TargetScanHuman The microarray data were deposited into the GEO database (accession no. GSE107008). 3 | RESULTS
| Expression levels of miR-451a in RCC clinical specimens and cell lines
Expression levels of miR-451a were significantly downregulated in RCC tissues compared with those in non-cancerous tissues (P = .0166; Figure 1A ). Furthermore, expression levels of miR-451a
in 786-O and A498 cells were markedly downregulated ( Figure 1A ).
F I G U R E 2
Flow chart illustrating the analytic strategy for miR451a targets in renal cell carcinoma cells. A total of 541 genes were putative targets of miR-451a in the TargetScan database analysis (release 7.0). We selected 16 genes as putative targets of miR-451a in renal cell carcinoma cells. GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas In the human genome, miR-451a has formed a miRNA cluster with other miRNAs (miR-144-5p, miR-144-3p, miR-451b, and miR-4732) on human chromosome 17q11.2 region ( Figure S1 ). We also checked expression of these miRNAs in RCC clinical specimens. Expression levels of miR-144-5p and miR-144-3p were significantly downregulated in RCC tissues. On the contrary, it was revealed that the expression levels of miR-451b and miR-4732 were extremely low in normal kidney and RCC tissues ( Figure S1 ).
To investigate the molecular mechanisms of silencing of miR451a in RCC cells, 786-O cells were treated with the demethylating agent 5-aza-2 0 -deoxycytidine. Expression of miR-451a was not dramatically elevated by 5-aza-2 0 -deoxycytidine treatment ( Figure S1 ).
A large cohort analysis (n = 506) using data from TCGA database showed that low expression of miR-451a was associated with poor survival of patients with RCC (P = .00305; Figure 1B ). 
| Screening of candidate targets by miR-451a regulation in RCC cells
We undertook in silico and gene expression analyses to identify genes targeted by miR-451a. The strategy for selection of miR-451a
target genes is shown in Figure 2 . Using the TargetScanHuman 7.0 database, we identified 541 genes that had putative target sites for miR-451a in their 3 0 -UTRs. Among these genes, we identified 64 that showed increased expression levels in RCC tissues (fold-change >1.5) using the database (GEO database accession number:
GSE36895).
Next, we identified 16 genes that were downregulated after transfection of 786-O and A498 cells with miR-451a (average log 2 ratio < À1.0; Table 2 ). Next, using the OncoLnc database, we investigated whether the expression levels of the 16 candidate genes affected the prognosis of RCC patients. Kaplan-Meier survival curves revealed that high expression levels of 9 of the genes were F I G U R E 3 The Cancer Genome Atlas database analysis of putative targets of miR-451a in renal cell carcinoma. Kaplan-Meier plots of overall survival with log-rank tests for 16 genes with high and low expression from The Cancer Genome Atlas database associated with poor prognosis in patients with RCC ( Figure 3) .
Finally, we focused on PMM2 because it showed the most evident difference in OncoLnc prognostic analysis (P = .000000218; Table 2 , Figure 3 ) and there are few reports on cancer studies.
| PMM2 directly regulated by miR-451a in RCC cells
Expression levels of PMM2/PMM2 were reduced by miR-451a transfection at mRNA and protein levels ( Figure 4A,B) .
Furthermore, we carried out luciferase reporter assays to elucidate whether PMM2 mRNA had a functional target site for miR451a. The TargetScan database predicted that miR-451a was bound at position 1127-1133 in the 3 0 -UTR of PMM2 ( Figure 4C ). We used vectors encoding a partial wild-type sequence of the 3 0 -UTR of PMM2 mRNA, including the predicted miR-451a target site, or a vector lacking the miR-451a target site. Luminescence intensity was significantly reduced by co-transfection with miR-451a and the vector carrying the wild-type 3 0 -UTR of PMM2. In contrast, luminescence intensity was not reduced when the target site of miR-451a was deleted from the vectors ( Figure 4D ).
| Effects of PMM2 knockdown in RCC cell lines
To investigate the functional significance of PMM2, we carried out loss-of-function studies using transfection of si-PMM2 into 786-O and A498 cells. First, we evaluated the knockdown efficiency of si-PMM2 transfection, using 2 types of si-PMM2 (si-PMM2_1 and si-PMM2_2). Using qRT-PCR and Western blot analyses, we confirmed that the expression levels of PMM2 mRNA and protein were significantly reduced ( Figure 5A,B) . Furthermore, functional assays showed that si-PMM2 transfection significantly inhibited cell proliferation, migration, and invasion in comparison with mock or siRNA-control transfected cells ( Figure 5C -E).
| Expression of PMM2/PMM2 in RCC clinical specimens and cell lines
We used qRT-PCR to investigate the mRNA expression levels of 
F I G U R E 4
Regulation of PMM2 expression by miR-451a in renal cell carcinoma cells. A, Expression levels of PMM2 mRNA 48 hours after transfection of 10 nmol/L miR-451a into cell lines. GUSB was used as an internal control. *P < .0001. B, Protein expression of phosphomannomutase 2 (PMM2) 72 hours after transfection with miR-451a. GAPDH was used as a loading control. C, miR-451a binding sites in the 3 0 -UTR of PMM2 mRNA. D, Dual luciferase reporter assays using vectors encoding putative miR-451a target sites (positions 1127-1133) in the PMM2 3 0 -UTR for both wild-type and deleted regions. Normalized data were calculated as the ratio of Renilla/firefly luciferase activities.
*P < .005
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Furthermore, Spearman's rank test revealed a negative correlation between the expression levels of miR-451a and PMM2 (P = .0409, R = À.38; Figure 6B ). Figure 6C ).
| Effects of co-transfection of PMM2/miR-451a in 786-O cells
We undertook PMM2 rescue studies in 786-O cells to elucidate whether the molecular pathway of PMM2/miR-451a was significant for the progression of RCC. Figure 7A These results suggested that PMM2 had an important role in the aggressiveness of RCC.
| Downstream genes affected by silencing of

PMM2 in 786-O cells
We carried out genome-wide gene expression analyses by transfecting si-PMM2 into 786-O cells to elucidate which genes were modulated by PMM2 knockdown. We focused on genes that were significantly downregulated by transfection of both si-PMM2_1 and si-PMM2_2 (average log 2 [si-PMM2/mock] < À1.0). Genes significantly downregulated by silencing of PMM2 are listed in Table 3 .
Among these genes, high expression levels of CD7, CCNE2, ASB2, RCN3, HSF1, PAQR4, CD37, SOX11, XAF1, and DEPDC1 were associated with poor prognosis in RCC patients based on TCGA database (Figure 8 ).
F I G U R E 5
Effects of PMM2 silencing in renal cell carcinoma cell lines. A, PMM2 mRNA expression 48 hours after transfection with 10 nM si-PMM2 into renal cell carcinoma cell lines. GUSB was used as an internal control. B, Phosphomannomutase 2 (PMM2) protein expression 72 h after transfection with si-PMM2. GAPDH was used as a loading control. C, Cell proliferation was determined with XTT assays 72 hours after transfection with 10 nM si-PMM2_1 or si-PMM2_2. D, Cell migration assessed by wound healing assays. E, Cell invasion activity was determined using a Matrigel system. *P < .0001
3.9 | Clinical significance of PMM2 in RCC pathogenesis using TCGA database
To investigate the clinical significance of PMM2 in RCC pathogenesis, we asked whether the PMM2 expression level affected diseasefree survival (DFS) in RCC. We found that high expression levels of PMM2 were significantly associated with low DFS in RCC patients (P < .0001; Figure 9A ). Furthermore, we analyzed the relationships among PMM2 expression levels and tumor T stage, lymph node metastasis, disease stage, and histologic grade in RCC. PMM2 expression levels were significantly higher in the more advanced tumor stages and histologic grades ( Figure 9B-E) .
Additionally, we undertook univariable and multivariable Cox hazard regression analyses to investigate the clinical significance of PMM2 expression along with other clinical factors in the overall survival of RCC patients. Multivariate analysis showed that high PMM2 expression and tumor stage were independent predictive factors for overall survival (hazard ratio = 1.26, P = .0487 and hazard ratio = 0.76, P = .0353, respectively; Table 4 ). These results suggested that PMM2 may be closely associated with tumor progression and malignancy in RCC.
| DISCUSSION
The aberrant expression of miRNAs disrupts regulated RNA networks in various type of cancer cells and therefore contributes substantially to the pathogenesis of human cancer. 30 Therefore, understanding miRNA signatures is essential to clarifying their roles in the pathology of human cancer cells. We previously characterized several miRNAs that had significant antitumor functions in RCC cells.
For example, miR-101 was significantly reduced in RCC tissues and the restoration of miR-101 inhibited RCC aggressiveness through targeting the UHRF1 gene. 9 More recently, we showed that miR10a-5p was downregulated in primary and tyrosine-kinase inhibitortreated RCC specimens and directly regulated the SKA1 gene. SKA1
was overexpressed and knockdown of SKA1 inhibited migration and invasion of RCC cells. 22 Our present data showed that expression of miR-451a was significantly reduced in primary RCC. Furthermore, ectopic expression of miR-451a resulted in inhibition of cancer cell migratory and invasive abilities in RCC, indicating that miR-451a functions as a tumor suppressor in RCC. Previous reports showed that expression of miR-451
was downregulated in several types of human cancers. In bladder cancer, miR-451 expression was significantly reduced in cancer tissues compared with adjacent tissues and that restoration of miR-451 reduced cancer cell migration and invasive abilities. 31, 32 Furthermore, low expression of miR-451 was associated with advanced tumor stage and high pathological grade in bladder cancer. 32 Our previous data showed that miR-451a acted as an antitumor miRNA through targeting ESDN/DCBLD2 in head and neck squamous cell carcinoma. 12 In this study, we identified 16 putative oncogenic targets by miR-451a regulation in RCC cells. Interestingly, among these targets,
Expression of PMM2 in clinical specimens of renal cell carcinoma. A, Expression levels of PMM2 in renal cell carcinoma clinical specimens. GUSB was used as an internal control. B, A negative correlation between PMM2 expression and miR-451a (R = À.38 and P = .0409). Spearman's rank test was used to evaluate the correlation. C, Immunostaining showed that phosphomannomutase 2 (PMM2) was strongly expressed in several cancer lesions (magnification, 9100 [left panels] and 9400 [right panels]) expression of 9 genes (PMM2, CRELD2, CLEC2D, SPC25, BST2, EVL, TBX15, DPYSL3, and NAMPT) were significantly associated with poor prognosis of the patients with RCC by TCGA database analyses.
These targets might be potential therapeutic targets for RCC and the search for RNA networks controlled by antitumor miR-451a and its targets are important for elucidation of the pathogenesis of RCC.
In the present study, we identified PMM2 as an oncogenic gene in RCC cells. Moreover, overexpressed PMM2 was involved RCC pathogenesis. PMM2 codes for an enzyme that converts mannose-6-phosphate to mannose-1-phosphate and participates in a metabolic pathway in glycan synthesis. [33] [34] [35] Protein glycosylation is an important contributor to cancer progression, including cell growth, tumorinduced immunomodulation, and eventual metastasis. 36 Previous reports indicated that cancer cells, including RCC, are characterized by an aberrant increase in protein N-glycosylation. 37, 38 In clear cell RCC, upregulation of protein glycosylation in cancer cells may be useful in diagnosis and determining disease prognosis. 39 Furthermore, N-glycosylation is involved in cell adhesion and is associated with reduced expression of E-cadherin, which modulates the metastatic potential of cancer cells. 37, 40 We hypothesize that this pathway might contribute to cancer pathogenesis such that upregulation of PMM2 might enhance cancer cell aggressiveness by increased N-glycosylation. In support of this hypothesis, TCGA database showed that high expression of PMM2 was associated with poor prognosis even in other types of cancer, for example, bladder cancer, breast cancer, head and neck squamous cell carcinoma, glioma, and melanoma ( Figure S2 ).
Interestingly, a previous report showed that miR-451 was controlled by glucose levels and regulated cancer aggressiveness through the AMP-activated protein kinase pathway and mTOR activation in glioblastoma. 15 Thus, miR-451 regulated pathways may be involved in glucose-related metabolic pathways and regulate cancer aggressiveness. Further research into miR-451/PMM2-modulated pathways in cancer will be necessary. To investigate PMM2-mediated pathways in RCC, we undertook genome-wide gene expression analyses using PMM2 knockdown cells. We identified 27 genes that were regulated by PMM2 in RCC. Among them, the expression of 10 genes was elevated (CD7, CCNE2, ASB2, RCN3, .03820000* GEO, Gene Expression Omnibus; OS, overall survival; TCGA, The Cancer Genome Atlas.
*, poor prognosis with low expression.
F I G U R E 8
The Cancer Genome Atlas database analysis of PMM2-mediated downstream genes in renal cell carcinoma. Kaplan-Meier curves of 10 genes whose high expression levels were associated with poor prognosis in renal cell carcinoma F I G U R E 9 Kaplan-Meier curves for disease-free survival based on PMM2 expression in patients with renal cell carcinoma, and expression levels of PMM2 according to T stage, N stage, tumor stage, and histologic grade. All patients' data were obtained from The Cancer Genome Atlas database. A, Kaplan-Meier survival curves for disease-free survival based on PMM2 expression in patients with renal cell carcinoma. B-E, Relationships between expression levels of PMM2 and T stage, N stage, disease stage, and histologic grade. *P < .05, **P < .005, ***P < .0001 HSF1, PAQR4, CD37, SOX11, XAF1, and DEPDC1) and their expression levels were significantly associated with poor prognosis in RCC patients according to TCGA database (P < .05). Elucidation of novel PMM2-mediated pathways may improve our understanding of RCC aggressiveness.
In conclusion, our data revealed that expression of miR-451a was significantly downregulated in clinical RCC cells. Moreover, miR-451a
acted as a tumor suppressor through the targeting of PMM2. Phosphomannomutase 2 was strongly expressed in RCC cells and its silencing significantly inhibited cancer cell migration and invasive abilities. In clinical analysis, high expression of PMM2 was significantly associated with shorter DFS and lower survival rates. In short, PMM2-regulated genes are deeply involved in RCC pathogenesis.
Elucidation of the pathways mediated by the miR-451a/PMM2 axis should improve our understanding of oncogenic mechanisms and lead to new treatment strategies in RCC.
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